当前位置:
X-MOL 学术
›
Cancer Discov.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Osimertinib May Be an Effective First-Line Therapy in EGFR-Mutant NSCLC
Cancer Discovery ( IF 29.7 ) Pub Date : 2017-09-08 , DOI: 10.1158/2159-8290.cd-rw2017-171 American Association for Cancer Research
中文翻译:
奥西替尼可能是EGFR突变型NSCLC的有效一线治疗
更新日期:2017-09-25
Cancer Discovery ( IF 29.7 ) Pub Date : 2017-09-08 , DOI: 10.1158/2159-8290.cd-rw2017-171 American Association for Cancer Research
Osimertinib achieved objective responses in 77% of patients with treatment-naïve NSCLC.
中文翻译:
奥西替尼可能是EGFR突变型NSCLC的有效一线治疗
Osimertinib在77%未接受过治疗的NSCLC患者中达到了客观反应。